Acadia pharmaceuticals announces health canada approval of daybue™ (trofinetide) for the treatment of rett syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that health canada has granted marketing authorization of daybue™ (trofinetide) for the treatment of rett syndrome in adult and pediatric patients two years of age and older under the priority review process. the notice of compliance authorization of daybue makes it the first and only drug approved in canada for the treatment of rett syndrome. rett syndrome is a rare, complex, neurodevelopmental disorder affe.
ACAD Ratings Summary
ACAD Quant Ranking